Início
Mercados
Gráficos e ideias
Algo
Notícias
Store
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
CASI
#3957
CASI Pharmaceuticals, Inc. Ordinary Shares
0.2
1
-73.75%
Setor:
Base:
Moeda do lucro:
Faixa diária
Faixa anual
Mudança diária
-73.75%
Mudança mensal
-78.79%
Mudança em 6 meses
-90.41%
Mudança anual
-91.36%
Fechamento anterior
0.8
0
Open
0.2
1
Bid
Ask
Low
0.2
1
High
0.2
1
Volume
17
Mercados
Ações
Cuidados de saúde
CASI
Open full chart
Financials
Overview
Relatórios
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
15.49 M
—
Valuation ratios
Enterprise value
30.34 M
—
Price to earnings ratio
-1.11
—
Price to sales ratio
—
—
Price to cash flow ratio
-1.49
—
Price to book ratio
23.45
—
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
0.51
—
Return on equity %
14.92
—
Return on invested capital %
-12.38
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
0.94
—
Current ratio
1.09
—
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
0.35
—
Long term debt to total equity ratio
10.21
—
Per share metrics
Operating cash flow per share
1.91
—
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
0.99
—
Net current asset value per share
2.58
—
Tangible book value per share
0.11
—
Working capital per share
0.2
—
Book value per share
0.12
—
Notícias
What Drove CASI Pharmaceuticals' 24% Rise After Hours? - CASI Pharmaceuticals (NASDAQ:CASI)
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.63%
E.U.A. - Ações fecharam o pregão em alta e o Índice Dow Jones Industrial Average avançou 0,63%
Ações da CASI Pharmaceuticals despencam após notificação de exclusão da Nasdaq
CASI Pharmaceuticals stock plunges on Nasdaq delisting notice
Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year?
Are Medical Stocks Lagging Alkermes (ALKS) This Year?
China approves CASI Pharmaceuticals’ CID-103 clinical trial for kidney rejection
Ações da CASI Pharmaceuticals disparam após Nasdaq conceder extensão de listagem
Casi Pharmaceuticals garante extensão de listagem na Nasdaq até fevereiro de 2026
CASI Pharmaceuticals stock surges after Nasdaq grants listing extension
Casi Pharmaceuticals secures Nasdaq listing extension until February 2026